Hyperoxaluria
Drug research and approvals for hyperoxaluria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 19, 2026, 16 studies of hyperoxaluria are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 4 approved and 8 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 16
- Trials authorized in Canada: 6
- FDA orphan approvals: 4
- EU medicines: 1
- Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1)NCT07776626 · Phase 1 · YolTech Therapeutics Co., Ltd · starts Aug 1, 2026
- A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With…NCT07681271 · Phase 2 · Novartis Pharmaceuticals · starts Jul 30, 2026
- Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)NCT07587021 · Phase 2 · YolTech Therapeutics Co., Ltd · starts Sep 16, 2026
- Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)NCT06839235 · Phase 1 / Phase 2 · Arbor Biotechnologies · starts Jun 16, 2025
- Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)NCT06511349 · Early Phase 1 · RenJi Hospital · starts Jul 15, 2024
- Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2…NCT06465472 · Phase 3 · Biocodex · starts Sep 23, 2026
- Gut Oxalate Absorption in Calcium Oxalate Stone DiseaseNCT06331546 · Not applicable · University of Alabama at Birmingham · starts Apr 17, 2024
- O. Formigenes Colonization in Calcium Oxalate Kidney Stone DiseaseNCT06330246 · Not applicable · University of Alabama at Birmingham · starts Apr 17, 2024
- Retrospective and Prospective Follow-up of Patients With Primary Hyperoxaluria Type 1 Treated With Lumasiran in France.NCT06225882 · Not reported · Hospices Civils de Lyon · starts Jan 1, 2023
| Jul 14, 2022 | Phase 1-2a safety, tolerability, and pharmacodynamics controlled study of NOV-001 in healthy volunteers and patients with enteric hyperoxaluriaNOV-001 (NB1000S / NB2000P) | Novome Biotechnologies, Inc. | Ongoing |
| Jul 6, 2021 | A phase 2 open-label multicenter study to evaluate the safety, pharmacokinetics, and efficacy of nedosiran in pediatric patients from birth to 5 years of age…Nedosiran (dcr-phxc) | Dicerna Pharmaceuticals Inc | Pending |
| Jul 10, 2019 | Evaluate the safety and efficacy of reloxaliase (oxalate decarboxylase) in patients with enteric hyperoxaluria: a phase III randomized, double-blind,…Reloxaliase (ALLN-177) | Allena Pharmaceuticals Inc | Ongoing |
| Mar 8, 2019 | An open-label roll-over study to evaluate the long-term safety and efficacy of dcr-phxc solution for injection (subcutaneous use) in patients with primary…Nedosiran (dcr-phxc) | Dicerna Pharmaceuticals Inc | Ongoing |
| Jan 21, 2019 | A phase 2 placebo-controlled, double-blind, multicenter study to evaluate the efficacy, safety, and tolerability of dcr-phxc solution for injection…Dcr-phxc | Dicerna Pharmaceuticals Inc | Closed |
| Aug 13, 2018 | A phase III double-blind, randomised study to evaluate the long-term efficacy and safety of oxabact in patients with primary hyperoxaluriaOxabact (OC5) | Oxthera Intellectual Property AB | Pending |
| Mar 27, 2025 | RivflozaTo lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively… | Dicerna Pharmaceuticals, Inc. (a wholly owned subsidiary of Novo Nordisk) | Approved |
| Sep 29, 2023 | RivflozaTo lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively… | Dicerna Pharmaceuticals, Inc. (a wholly owned subsidiary of Novo Nordisk) | Approved |
| Oct 6, 2022 | OxlumoTreatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients | Alnylam Pharmaceuticals | Approved |
| Nov 23, 2020 | OxlumoTreatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients | Alnylam Pharmaceuticals | Approved |
| Feb 2, 2025 | A lipid nanoparticle encapsulating a messenger RNA for the…Treatment of primary hyperoxaluria | Arbor Biotechnologies, Inc. | Designated |
| Sep 20, 2024 | Lipid nanoparticles containing CRISPR/Cas12HF mRNA and a…Treatment of primary hyperoxaluria | Yoltech Therapeutics Co., Ltd | Designated |
| Aug 21, 2024 | A small molecule dual inhibitor of the enzymes LDHA and…Treatment of primary hyperoxaluria | Meta Pharmaceuticals (HK) Ltd | Designated |
| Feb 22, 2021 | StiripentolTreatment of Primary Hyperoxaluria | Biocodex | Designated |
| Jun 12, 2017 | Bacillus subtilis oxalate decarboxylaseTreatment of primary hyperoxaluria | Allena Pharmaceuticals, Inc. | Designated |
| Feb 29, 2016 | Bacillus subtilis oxalate decarboxylaseTreatment of pediatric hyperoxaluria | Allena Pharmaceuticals, Inc. | Designated |
| Apr 22, 2015 | Synthetic double-stranded (hybridized duplex) ribonucleic…Treatment of primary hyperoxaluria type 1 | Dicerna Pharmaceuticals, Inc. | Designated |
| Mar 29, 2006 | Oxalobacter formigenesTreatment of primary hyperoxaluria | OxThera Inc. | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Nov 19, 2020 | OxlumoLumasiran · orphan | Alnylam Netherlands B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA